{"prompt": "['Protocol RS-001', 'Confidential', 'intrathoracic metastases had a confirmed PR. The target lesion of this participant was reduced by', '35.1% and the duration of response lasted 183 days. Two (11%) participants (at doses 45 and', '125 mg/m\u00b2, with actual rapamycin doses of 88 mg and 193 mg, respectively) had an overall', 'tumor evaluation of SD (confirmed): 1 participant with mesothelioma had SD for 365 days and 1', 'participant with a neuroendocrine tumor in the left axillary node had SD for 238 days.', 'For all cohorts and all grades, 25 of 26 (96%) participants experienced at least 1 treatment-', 'related adverse event (TRAE). The most common nonhematologic TRAEs reported were', 'mucosal inflammation (10 participants, 38%), fatigue (7 participants, 27%), rash (6 participants,', '23%), diarrhea (6 participants, 23%), and nausea (5 participants, 19%). Most of these AEs were', 'grade 1/2 events, with only three grade 3 nonhematologic AEs (2 elevated AST and 1 dyspnea).', 'Specifically, at the MTD (100 mg/m\u00b2), all 7 participants experienced at least 1 TRAE of any', 'grades, and the most common AEs were thrombocytopenia, mucositis, and fatigue (5', 'participants, 71% each). A total of 7 participants (27%) had infections, including candidiasis,', 'oral candidiasis, cellulitis, folliculitis, and urinary tract infection. All these events were grade 1', 'or 2.', 'Four (15%) participants experienced at least 1 treatment-related serious AE, including cardiac', 'arrhythmia (grade 2) and mood alteration (grade 3) both in the 125 mg/m\u00b2 cohort, vomiting', '(grade 3) in the 45 mg/m\u00b2 cohort, and dyspnea (grade 3) in the 100 mg/m\u00b2 cohort.', 'The most common hematologic TRAE, for all cohorts and grades, were thrombocytopenia', '(58%), followed by hypokalemia (23%), anemia and hypophosphatemia (19% each), and', 'neutropenia (15%). Most of these events were grade 1/2, and only one grade 4 hematologic event', 'occurred (thrombocytopenia in the 150 mg/m\u00b2 arm). At the MTD, the only hematologic AE was', 'a grade 3 anemia.', 'Study PEC-001 (Malignant PEComa)', 'Study PEC-001 is a phase 2, multi-center, single arm, open-label, multi-institutional study to', 'determine the efficacy and safety profile of ABI-009 administered by IV infusion in participants', 'with malignant PEComa. The primary objective of this study is to investigate the efficacy of the', 'mTOR inhibitor ABI-009 in advanced malignant PEComa. The secondary objectives are to', 'further investigate the efficacy and safety of intravenous (IV) ABI-009 100 mg/m\u00b2 given weekly', 'for 2 of 3 weeks in participants with advanced malignant PEComa. At least 30 evaluable', 'participants will be enrolled in study PEC-001.', 'Study PAH-001 (Severe Pulmonary Arterial Hypertension)', 'This study is a prospective phase 1, single arm, open-label, multi-institutional study to determine', 'the MTD, safety, and preliminary efficacy of IV ABI-009 in participants with severe PAH. ABI-', '009 is administered weekly for 16 weeks with a dose range of 1-10 mg/m\u00b2.', \"More information is provided in the ABI-009 Investigator's Brochure.\", '1.12 Clinical Experience with ABI-009 in Pediatric Participants', 'ABI-009 is currently being investigated in a multicenter phase 1 study (ADVL1514) by the', \"Children's Oncology Group (COG) in pediatric participants with recurrent or refractory solid\", 'tumors. The aims of the trial will be to establish the maximum tolerated pediatric dose of ABI-', '009 administered as an intravenous infusion over 30 minutes on Days 1 and 8 of a 21-day cycle,', 'in combination with temozolomide and irinotecan (administered on Days 1-5), and to investigate', 'Version 2', 'Version Date: October 31, 2018', 'Page 27 of 72']['Protocol RS-001', 'Confidential', 'the toxicities, pharmacokinetics, and pharmacodynamics of ABI-009 in pediatric participants', 'with recurrent or refractory solid tumors, including CNS tumors. The study uses the Rolling Six', 'escalation/de-escalation design, and the starting dose of ABI-009 is 35 mg/m\u00b2.', 'As of Jan 30, 2018, 6 participants have been enrolled and received treatment. Overall, the', 'adverse events observed with ABI-009 in pediatric participants are consistent with those', 'observed in previous clinical studies in adults. The main dose limiting toxicity of ABI-009,', 'administered as a single agent and in combination with cytotoxic agents temozolomide and', 'irinotecan, is grade 3 thrombocytopenia (2 out of 5 participants receiving ABI-009 at 35 mg/m\u00b2).', 'As per the protocol de-escalation guidelines, the new cohort of participants will receive an ABI-', '009 dose of 20 mg/m\u00b2 in combination with temozolomide and irinotecan.', '1.13 Comparison of Exposure of ABI-009 and Oral mTOR Inhibitors', 'Preclinical and clinical PK studies showed that ABI-009 administered IV exhibits an overall', 'linear PK (Cmax and AUC) with respect to dose. In contrast, oral rapamycin has poor', 'bioavailability (14% with oral solution, 18% with tablet) and its uptake is affected by food [147].', 'The oral bioavailability is higher with everolimus at ~30% but is still heavily affected by food,', 'which can reduce Cmax by ~60% and AUC by -16% [143]. Clinically, administration of ABI-009', 'at the maximum tolerated dose of 100 mg/m\u00b2 IV weekly led to a much higher drug exposure as', 'compared with daily oral rapamycin at 5 mg/day (Cmax 130-200 fold, AUC 16-27 fold higher', 'with ABI-009) and oral everolimus at 4-10 mg/day (Cmax 50-70 fold, AUC 12-29 fold higher', 'with ABI-009) [130, 143, 144]. The exposure normalized to dose (AUC/dose) is also', 'significantly higher with ABI-009 compared with oral rapamycin (~3-5 fold) and oral everolimus', '(~4-5 fold) [130, 143, 144].', 'PK modeling and limited clinical data have also suggested that weekly IV administration of ABI-', '009 at doses similar to or lower than oral rapamycin and everolimus can achieve a weekly trough', 'rapamycin blood level within the targeted therapeutic range of 5-15 ng/ml with oral mTOR', 'inhibitors. In the current study, the starting dose of ABI-009 is 5 mg/m2/week, with potential', 'dose escalation to 10 and 20 mg/m2/week or de-escalation to 2.5 and 1 mg/m2/week. Linear', 'modeling of rapamycin blood concentration one week after ABI-009 IV administration using', 'phase 1 clinical PK data indicates that a weekly dose of ABI-009 at 5-20 mg/m\u00b2 can still', 'maintain a relevant therapeutic weekly whole blood rapamycin trough level (see table below)', 'with doses below 5 mg/m\u00b2 reaching somewhat lower levels.', 'Table 1:', 'Predicted Rapamycin Blood Levels after ABI-009 IV Administration', 'Dose', 'Time Post-infusion (hr)', '(mg/m\u00b2)', '0', '1', '4', '8', '24', '48', '72', '96', '168', '1', '28.44', '9.45', '7.40', '5.20', '3.64', '2.43', '1.42', '1.39', '0.71', '2', '56.88', '18.89', '14.80', '10.39', '7.27', '4.86', '2.84', '2.79', '1.42', '3', '85.32', '28.34', '22.20', '15.59', '10.91', '7.29', '4.26', '4.18', '2.13', '5', '142.20', '47.23', '37.00', '25.99', '18.18', '12.15', '7.10', '6.97', '3.56', '10', '284.40', '94.46', '73.99', '51.97', '36.35', '24.30', '14.20', '13.94', '7.11', '20', '568.80', '188.92', '147.98', '103.94', '72.70', '48.60', '28.40', '27.88', '14.22', 'Version 2', 'Version Date: October 31, 2018', 'Page 28 of 72']\n\n###\n\n", "completion": "END"}